Tags

Type your tag names separated by a space and hit enter

Emerging therapies in rosacea.
J Am Acad Dermatol. 2013 Dec; 69(6 Suppl 1):S57-65.JA

Abstract

Rosacea is a common skin disorder with multiple symptoms. The emergence of research that furthers understanding of pathophysiological mechanisms has created new targets for disease treatment. Specifically, there is a need for new treatments that address the various erythematic symptoms associated with rosacea. Systemic and topical therapies have both yielded positive results in treating rosacea with various medications. Subantimicrobial-dose doxycycline is one such promising treatment. Development of novel products in the near future should help achieve more satisfactory outcomes for patients.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Layton A
Department of Dermatology, Harrogate District Hospital, United Kingdom. Electronic address: Alison.layton@hhc-tr.northy.nhs.uk.
Thiboutot D
No affiliation info available

MeSH

Anti-Bacterial AgentsAntiparasitic AgentsCytokinesDoxycyclineErythemaHumansIvermectinMite InfestationsPermethrinRosacea

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24229638

Citation

Layton, Alison, and Diane Thiboutot. "Emerging Therapies in Rosacea." Journal of the American Academy of Dermatology, vol. 69, no. 6 Suppl 1, 2013, pp. S57-65.
Layton A, Thiboutot D. Emerging therapies in rosacea. J Am Acad Dermatol. 2013;69(6 Suppl 1):S57-65.
Layton, A., & Thiboutot, D. (2013). Emerging therapies in rosacea. Journal of the American Academy of Dermatology, 69(6 Suppl 1), S57-65. https://doi.org/10.1016/j.jaad.2013.04.041
Layton A, Thiboutot D. Emerging Therapies in Rosacea. J Am Acad Dermatol. 2013;69(6 Suppl 1):S57-65. PubMed PMID: 24229638.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging therapies in rosacea. AU - Layton,Alison, AU - Thiboutot,Diane, PY - 2013/04/16/received PY - 2013/04/21/accepted PY - 2013/11/16/entrez PY - 2013/11/28/pubmed PY - 2014/2/18/medline KW - SDD KW - carvedilol KW - ivermectin KW - medical therapy KW - permethrin KW - rosacea KW - subantimicrobial dose doxycycline KW - subantimicrobial-dose doxycycline SP - S57 EP - 65 JF - Journal of the American Academy of Dermatology JO - J Am Acad Dermatol VL - 69 IS - 6 Suppl 1 N2 - Rosacea is a common skin disorder with multiple symptoms. The emergence of research that furthers understanding of pathophysiological mechanisms has created new targets for disease treatment. Specifically, there is a need for new treatments that address the various erythematic symptoms associated with rosacea. Systemic and topical therapies have both yielded positive results in treating rosacea with various medications. Subantimicrobial-dose doxycycline is one such promising treatment. Development of novel products in the near future should help achieve more satisfactory outcomes for patients. SN - 1097-6787 UR - https://brain.unboundmedicine.com/medline/citation/24229638/Emerging_therapies_in_rosacea_ DB - PRIME DP - Unbound Medicine ER -